Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 14 2013 Cyclacel Reports Second Quarter 2013 Financial Results Aug 12 2013 Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis Aug 08 2013 Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial Results Jul 05 2013 Cyclacel Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2013 May 21 2013 Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering May 16 2013 Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering May 15 2013 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock May 13 2013 Cyclacel Reports First Quarter 2013 Financial Results May 10 2013 Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Results Apr 30 2013 Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS Apr 23 2013 Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference Apr 09 2013 Combination Potential of Cyclacel's Sapacitabine and Seliciclib Reported at AACR Apr 08 2013 AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs Apr 04 2013 Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation Apr 03 2013 Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting Mar 27 2013 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results Mar 22 2013 Cyclacel to Announce Year-End and Fourth Quarter 2012 Financial Results Feb 12 2013 Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors Feb 04 2013 Cyclacel Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Jan 07 2013 Cyclacel Reviews 2012 Achievements and Announces Key Business Objectives for 2013 Dec 17 2012 Cyclacel Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC Dec 10 2012 2012 ASH 682-11 Pilot and CYC682-12 lead-in Poster Dec 10 2012 Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting Dec 04 2012 Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting Nov 12 2012 Cyclacel Reports Third Quarter 2012 Financial Results Pagination First page « first Previous page ‹ previous … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 14 2013 Cyclacel Reports Second Quarter 2013 Financial Results Aug 12 2013 Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis Aug 08 2013 Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial Results Jul 05 2013 Cyclacel Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2013 May 21 2013 Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering May 16 2013 Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering May 15 2013 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock May 13 2013 Cyclacel Reports First Quarter 2013 Financial Results May 10 2013 Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Results Apr 30 2013 Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS Apr 23 2013 Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference Apr 09 2013 Combination Potential of Cyclacel's Sapacitabine and Seliciclib Reported at AACR Apr 08 2013 AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs Apr 04 2013 Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation Apr 03 2013 Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting Mar 27 2013 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results Mar 22 2013 Cyclacel to Announce Year-End and Fourth Quarter 2012 Financial Results Feb 12 2013 Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors Feb 04 2013 Cyclacel Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Jan 07 2013 Cyclacel Reviews 2012 Achievements and Announces Key Business Objectives for 2013 Dec 17 2012 Cyclacel Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC Dec 10 2012 2012 ASH 682-11 Pilot and CYC682-12 lead-in Poster Dec 10 2012 Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting Dec 04 2012 Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting Nov 12 2012 Cyclacel Reports Third Quarter 2012 Financial Results Pagination First page « first Previous page ‹ previous … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Next page next › Last page last »
Aug 12 2013 Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis
Apr 04 2013 Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation
Apr 03 2013 Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting
Feb 12 2013 Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors
Dec 17 2012 Cyclacel Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Dec 10 2012 Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting
Dec 04 2012 Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting
